XML 30 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Cash Flows from Operating Activities    
Net income (loss) $ 19,160 $ (10,071)
Adjustments to reconcile net income (loss) to net cash from operating activities:    
Depreciation and amortization 5,771 3,927
Deferred income taxes (798) (6,215)
Non-cash equity-based compensation 4,722 2,579
Provision for bad debt (42) 16
Gross profit from sales of lab tools (920)  
Change in contingent consideration (29,368)  
Excess tax benefits from equity-based compensation   (31)
Changes in operating assets and liabilities:    
Accounts receivable (26,939) 20,004
Restricted cash 1,974  
Inventories 8,150 (8,395)
Prepaid expenses and other current assets (3,410) (6,501)
Accounts payable (7,432) 6,458
Accrued expenses, customer deposits, deferred revenue and other current liabilities 11,608 1,764
Income taxes payable (612) (1,555)
Other, net (265) 8,506
Net cash provided by (used in) operating activities (18,401) 10,486
Cash Flows from Investing Activities    
Capital expenditures (2,138) (1,619)
Proceeds from the liquidation of short-term investments 32,030 101,236
Payments for purchases of short-term investments (17,989) (271,713)
Proceeds from sale of lab tools 2,340  
Other (124)  
Net cash provided by (used in) investing activities 14,119 (172,096)
Cash Flows from Financing Activities    
Proceeds from stock option exercises 8,316 280
Restricted stock tax withholdings (170) (132)
Excess tax benefits from equity-based compensation   31
Repayments of long-term debt (70) (65)
Net cash provided by (used in) financing activities 8,076 114
Effect of exchange rate changes on cash and cash equivalents 89 60
Net increase (decrease) in cash and cash equivalents 3,883 (161,436)
Cash and cash equivalents as of beginning of period 210,799 384,557
Cash and cash equivalents as of end of period $ 214,682 $ 223,121